Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF).In 28,628 patients prospectively enrolled in the GARFIELD-AF registry...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5784935?pdf=render |
id |
doaj-75beec487231485fb194868fd5e970bb |
---|---|
record_format |
Article |
spelling |
doaj-75beec487231485fb194868fd5e970bb2020-11-25T01:22:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01131e019159210.1371/journal.pone.0191592Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.Jean-Pierre BassandGabriele AccettaWael Al MahmeedRamon CorbalanJohn EikelboomDavid A FitzmauriceKeith A A FoxHaiyan GaoSamuel Z GoldhaberShinya GotoSylvia HaasGloria KayaniKaren PieperAlexander G G TurpieMartin van EickelsFreek W A VerheugtAjay K KakkarGARFIELD-AF InvestigatorsThe factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF).In 28,628 patients prospectively enrolled in the GARFIELD-AF registry with 2-year follow-up, we aimed at analysing: (1) the variables influencing outcomes; (2) the extent of implementation of guideline-recommended therapies in comorbidities that strongly affect outcomes. Median (IQR) age was 71.0 (63.0 to 78.0) years, 44.4% of patients were female, median (IQR) CHA2DS2-VASc score was 3.0 (2.0 to 4.0); 63.3% of patients were on anticoagulants (ACs) with or without antiplatelet (AP) therapy, 24.5% AP monotherapy, and 12.2% no antithrombotic therapy. At 2 years, rates (95% CI) of death, stroke/SE, and major bleeding were 3.84 (3.68; 4.02), 1.27 (1.18; 1.38), and 0.71 (0.64; 0.79) per 100 person-years. Age, history of stroke/SE, vascular disease (VascD), and chronic kidney disease (CKD) were associated with the risks of all three outcomes. Congestive heart failure (CHF) was associated with the risks of death and stroke/SE. Smoking, non-paroxysmal forms of AF, and history of bleeding were associated with the risk of death, female sex and heavy drinking with the risk of stroke/SE. Asian race was associated with lower risks of death and major bleeding versus other races. AC treatment was associated with 30% and 28% lower risks of death and stroke/SE, respectively, compared with no AC treatment. Rates of prescription of guideline-recommended drugs were suboptimal in patients with CHF, VascD, or CKD.Our data show that several variables are associated with the risk of one or more outcomes, in terms of death, stroke/SE, and major bleeding. Comprehensive management of AF should encompass, besides anticoagulation, improved implementation of guideline-recommended therapies for comorbidities strongly associated with outcomes, namely CHF, VascD, and CKD.ClinicalTrials.gov NCT01090362.http://europepmc.org/articles/PMC5784935?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jean-Pierre Bassand Gabriele Accetta Wael Al Mahmeed Ramon Corbalan John Eikelboom David A Fitzmaurice Keith A A Fox Haiyan Gao Samuel Z Goldhaber Shinya Goto Sylvia Haas Gloria Kayani Karen Pieper Alexander G G Turpie Martin van Eickels Freek W A Verheugt Ajay K Kakkar GARFIELD-AF Investigators |
spellingShingle |
Jean-Pierre Bassand Gabriele Accetta Wael Al Mahmeed Ramon Corbalan John Eikelboom David A Fitzmaurice Keith A A Fox Haiyan Gao Samuel Z Goldhaber Shinya Goto Sylvia Haas Gloria Kayani Karen Pieper Alexander G G Turpie Martin van Eickels Freek W A Verheugt Ajay K Kakkar GARFIELD-AF Investigators Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE |
author_facet |
Jean-Pierre Bassand Gabriele Accetta Wael Al Mahmeed Ramon Corbalan John Eikelboom David A Fitzmaurice Keith A A Fox Haiyan Gao Samuel Z Goldhaber Shinya Goto Sylvia Haas Gloria Kayani Karen Pieper Alexander G G Turpie Martin van Eickels Freek W A Verheugt Ajay K Kakkar GARFIELD-AF Investigators |
author_sort |
Jean-Pierre Bassand |
title |
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. |
title_short |
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. |
title_full |
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. |
title_fullStr |
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. |
title_full_unstemmed |
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. |
title_sort |
risk factors for death, stroke, and bleeding in 28,628 patients from the garfield-af registry: rationale for comprehensive management of atrial fibrillation. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF).In 28,628 patients prospectively enrolled in the GARFIELD-AF registry with 2-year follow-up, we aimed at analysing: (1) the variables influencing outcomes; (2) the extent of implementation of guideline-recommended therapies in comorbidities that strongly affect outcomes. Median (IQR) age was 71.0 (63.0 to 78.0) years, 44.4% of patients were female, median (IQR) CHA2DS2-VASc score was 3.0 (2.0 to 4.0); 63.3% of patients were on anticoagulants (ACs) with or without antiplatelet (AP) therapy, 24.5% AP monotherapy, and 12.2% no antithrombotic therapy. At 2 years, rates (95% CI) of death, stroke/SE, and major bleeding were 3.84 (3.68; 4.02), 1.27 (1.18; 1.38), and 0.71 (0.64; 0.79) per 100 person-years. Age, history of stroke/SE, vascular disease (VascD), and chronic kidney disease (CKD) were associated with the risks of all three outcomes. Congestive heart failure (CHF) was associated with the risks of death and stroke/SE. Smoking, non-paroxysmal forms of AF, and history of bleeding were associated with the risk of death, female sex and heavy drinking with the risk of stroke/SE. Asian race was associated with lower risks of death and major bleeding versus other races. AC treatment was associated with 30% and 28% lower risks of death and stroke/SE, respectively, compared with no AC treatment. Rates of prescription of guideline-recommended drugs were suboptimal in patients with CHF, VascD, or CKD.Our data show that several variables are associated with the risk of one or more outcomes, in terms of death, stroke/SE, and major bleeding. Comprehensive management of AF should encompass, besides anticoagulation, improved implementation of guideline-recommended therapies for comorbidities strongly associated with outcomes, namely CHF, VascD, and CKD.ClinicalTrials.gov NCT01090362. |
url |
http://europepmc.org/articles/PMC5784935?pdf=render |
work_keys_str_mv |
AT jeanpierrebassand riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT gabrieleaccetta riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT waelalmahmeed riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT ramoncorbalan riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT johneikelboom riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT davidafitzmaurice riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT keithaafox riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT haiyangao riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT samuelzgoldhaber riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT shinyagoto riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT sylviahaas riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT gloriakayani riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT karenpieper riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT alexanderggturpie riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT martinvaneickels riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT freekwaverheugt riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT ajaykkakkar riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation AT garfieldafinvestigators riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation |
_version_ |
1725125160779907072 |